8-K: Avenue Therapeutics Faces Nasdaq Delisting Risk Amidst License Dispute

Avenue Therapeutics is navigating Nasdaq compliance issues and a dispute over a key license agreement, casting uncertainty over its future.

Summary

• Avenue Therapeutics is facing potential delisting from the Nasdaq Capital Market due to non-compliance with the minimum stockholders' equity requirement.
• The Nasdaq Hearings Panel granted an exception for continued listing, contingent on the company disclosing equity-increasing transactions, providing updated fundraising plans and income projections by March 14, 2025, and announcing clinical trial results for the AJ201 program by April 15, 2025.
• Avenue is also in a dispute with AnnJi Pharmaceutical Co. regarding the license agreement for AJ201, a clinical product candidate for treating spinal and bulbar muscular atrophy.
• AnnJi has issued a notice to terminate the license agreement, citing alleged breaches by Avenue, which Avenue disputes.
• Avenue has submitted a Request for Emergency Measures with the International Court of Arbitration to prevent AnnJi from deploying an assay it believes is materially defective.
• The company believes the purported termination is invalid and intends to pursue its rights under the agreement and by law.
• Avenue acknowledges substantial doubt about its ability to continue as a going concern and the need for additional funding.

Sentiment

Score: 3

Explanation: The document presents significant challenges for Avenue Therapeutics, including potential delisting from Nasdaq and a dispute over a key license agreement. The company's ability to continue as a going concern is also in doubt, leading to a negative sentiment.

Positives

• The Nasdaq Hearings Panel granted an exception for continued listing, providing Avenue Therapeutics with an opportunity to regain compliance.
• Avenue Therapeutics intends to pursue all rights provided to it under the License Agreement and by law.

Negatives

• Avenue Therapeutics received a Nasdaq delisting letter due to non-compliance with the minimum stockholders' equity requirement.
• AnnJi Pharmaceutical Co. issued a notice to terminate the license agreement for AJ201, citing alleged breaches by Avenue.
• Avenue acknowledges substantial doubt about its ability to continue as a going concern.

Risks

• Failure to meet the conditions set by the Nasdaq Hearings Panel could result in delisting.
• The dispute with AnnJi Pharmaceutical Co. could jeopardize the development of AJ201.
• The company's ability to continue as a going concern is uncertain due to substantial doubt and the need for additional funding.
• The company may not receive regulatory approval for any or all of our product candidates, or that such approval may be significantly delayed due to scientific or regulatory reasons.
• The company's failure to satisfy applicable listing standards of the Nasdaq Capital Market resulting in a potential delisting of our common stock.

Future Outlook

The company is considering all options available to it to regain compliance with the Stockholders Equity Requirement; however, there can be no assurance that the Company will be able to do so.

Management Comments

• The Company firmly believes that the grounds for termination of the License Agreement stated in the Purported Termination Notice are without merit and intends to pursue all rights provided to it under the License Agreement and by law.
• Accordingly, the Company believes that the purported termination of the License Agreement in the Purported Termination Notice is invalid and of no force and effect, and that the License Agreement remains a valid and binding agreement.

Industry Context

The dispute over the license agreement highlights the risks associated with relying on partnerships for drug development. Many small biotech companies rely on larger pharmaceutical companies or other entities to license and develop their products. Any breakdown in these relationships can significantly impact the company's prospects.

Comparison to Industry Standards

• Many small-cap biotech companies face challenges in maintaining Nasdaq listing compliance, particularly regarding minimum stockholders' equity.
• Companies like BioLineRx and Diffusion Pharmaceuticals have faced similar delisting warnings and have implemented strategies such as reverse stock splits or capital raises to regain compliance.
• License agreement disputes are also common in the pharmaceutical industry, with companies like Galapagos and AbbVie having faced disagreements over drug development and commercialization rights.
• The outcome of Avenue's dispute with AnnJi will be closely watched by other companies in the industry, as it could set a precedent for how such disagreements are resolved.

Legal Proceedings

• Avenue submitted a Request for Emergency Measures with the International Court of Arbitration seeking to prevent the deployment of such assay.

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment value.
• Employees face uncertainty regarding the company's future and potential job security.
• The dispute with AnnJi could impact the development of AJ201, affecting patients with spinal and bulbar muscular atrophy.
• Creditors face increased risk due to the company's financial challenges.

Next Steps

• Avenue Therapeutics must make public disclosure describing any transactions undertaken by the Company to increase its equity and provide an indication of its equity following those transactions by March 14, 2025.
• Avenue Therapeutics must provide the Panel with an update on its fundraising plans and updated income projections for the next 12 months by March 14, 2025.
• Avenue Therapeutics must file a Current Report on Form 8-K announcing the results of the read out from the clinical trial for the Company's AJ201 program by April 15, 2025.
• Avenue Therapeutics intends to pursue all rights provided to it under the License Agreement and by law.

Key Dates